Department of Science and Environment, Roskilde University, Universitetsvej 1, 4000 Roskilde, Denmark.
Department of Clinical Immunology, Zealand University Hospital, Køge, Ringstedgade 77B, 4700 Næstved, Denmark.
Biomolecules. 2023 May 22;13(5):871. doi: 10.3390/biom13050871.
In this study, we conducted a systematic review and meta-analysis to summarize and evaluate the global research potential of different circulating miRNAs as an early diagnostic biomarker for OC. A systematic literature search for relevant studies was conducted in June 2020 and followed up in November 2021. The search was conducted in English databases (PubMed, ScienceDirect). The primary search resulted in a total of 1887 articles, which were screened according to the prior established inclusion and exclusion criteria. We identified 44 relevant studies, of which 22 were eligible for the quantitative meta-analysis. Statistical analysis was performed using the Meta-package in Rstudio. Standardized mean differences (SMD) of relative levels between control subjects and OC patients were used to evaluate the differential expression. All studies were quality evaluated using a Newcastle-Ottawa Scale. Based on the meta-analysis, nine miRNAs were identified as dysregulated in OC patients compared to controls. Nine were upregulated in OC patients compared to controls (miR-21, -125, -141, -145, -205, -328, -200a, -200b, -200c). Furthermore, miR-26, -93, -106 and -200a were analyzed, but did not present an overall significant difference between OC patients and controls. These observations should be considered when performing future studies of circulating miRNAs in relation to OC: sufficient size of clinical cohorts, development of consensus guidelines for circulating miRNA measurements, and coverage of previously reported miRNAs.
在这项研究中,我们进行了系统评价和荟萃分析,以总结和评估不同循环 miRNA 作为卵巢癌早期诊断生物标志物的全球研究潜力。系统检索了 2020 年 6 月和 2021 年 11 月的相关研究。检索是在英文数据库(PubMed、ScienceDirect)中进行的。初步检索共得到 1887 篇文章,根据预先确定的纳入和排除标准进行筛选。我们确定了 44 项相关研究,其中 22 项符合定量荟萃分析的条件。使用 Rstudio 中的 Meta-package 进行统计分析。采用标准化均数差值(SMD)来评估对照组和 OC 患者之间相对水平的差异表达。使用纽卡斯尔-渥太华量表对所有研究进行质量评估。基于荟萃分析,确定了 9 种 miRNA 在 OC 患者中与对照组相比存在失调。与对照组相比,9 种 miRNA 在 OC 患者中上调(miR-21、-125、-141、-145、-205、-328、-200a、-200b、-200c)。此外,还分析了 miR-26、-93、-106 和 -200a,但它们在 OC 患者和对照组之间没有表现出总体显著差异。在进行与 OC 相关的循环 miRNA 未来研究时,应考虑到这些观察结果:足够大的临床队列规模、制定循环 miRNA 测量的共识指南、以及涵盖先前报道的 miRNA。